Sutura Therapeutics: New CEO

Beards assumes this role from his prior role as Non-Executive Director of the British biotech company. For more than 25 years, he has been active in the Life Sciences. He has previously held a broad range of roles across the value chain of biotechnology and pharmaceuticals, including as CEO at Utility Therapeutics, Group CFO at Celixir plc, and additionally at KPMG, Charles River Associatios, Goldman Sachs, McKinsey & Company, GSK and Abbott Laboratories. Beards holds a BA and MA in Mathematics and he is a qualified Chartered management Accountant.

At the beginning of March, James Noble and Eduardo Bravo became members of the Sutura Board of Directors, Noble as chairman of the board.